Application of Physiologically Based Pharmacokinetic Modeling to Evaluate the Drug–Drug and Drug–Disease Interactions of Apatinib

Aim: Apatinib is an orally administered vascular epidermal growth factor receptor (VEGFR)-tyrosine kinase inhibitors approved for the treatment of advanced gastric adenocarcinoma or gastric esophageal junction adenocarcinoma. Apatinib is predominantly metabolized by CYP3A4/5, followed by CYP2D6. The...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Hongrui, Yu, Yiqun, Guo, Nan, Wang, Xiaojuan, Han, Bing, Xiang, Xiaoqiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8645681/
https://www.ncbi.nlm.nih.gov/pubmed/34880763
http://dx.doi.org/10.3389/fphar.2021.780937

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8645681/
https://www.ncbi.nlm.nih.gov/pubmed/34880763
http://dx.doi.org/10.3389/fphar.2021.780937

Ejemplares similares